Novavax (NVAX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to -$762.9 million.
- Novavax's Enterprise Value rose 1611.91% to -$762.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$762.9 million, marking a year-over-year increase of 1611.91%. This contributed to the annual value of -$923.1 million for FY2024, which is 6237.64% down from last year.
- Per Novavax's latest filing, its Enterprise Value stood at -$762.9 million for Q3 2025, which was up 1611.91% from -$612.3 million recorded in Q2 2025.
- In the past 5 years, Novavax's Enterprise Value ranged from a high of -$480.6 million in Q1 2024 and a low of -$2.1 billion during Q2 2021
- Moreover, its 5-year median value for Enterprise Value was -$923.1 million (2024), whereas its average is -$1.1 billion.
- Its Enterprise Value has fluctuated over the past 5 years, first crashed by 74166.42% in 2021, then surged by 6322.21% in 2023.
- Quarter analysis of 5 years shows Novavax's Enterprise Value stood at -$1.5 billion in 2021, then rose by 11.76% to -$1.3 billion in 2022, then skyrocketed by 57.48% to -$568.5 million in 2023, then crashed by 62.38% to -$923.1 million in 2024, then grew by 17.35% to -$762.9 million in 2025.
- Its Enterprise Value was -$762.9 million in Q3 2025, compared to -$612.3 million in Q2 2025 and -$731.5 million in Q1 2025.